For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...
"Medtronic is the only company in the world to offer an adaptive DBS system that dynamically adjusts therapy in real time," said Brett Wall, executive vice president and president of the Medtronic ...
Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense ...
The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy personalization and clinic efficiency.
On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease.
Medtronic's Percept™ DBS neurostimulators now incorporate BrainSense™ Adaptive technology, which allows the system to automatically adjust therapy without manual intervention by patients or ...
"Medtronic is the only company in the world to offer an adaptive DBS system that dynamically adjusts therapy in real time," said Brett Wall, executive vice president and president of the Medtronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback